Skip to main navigation

Live - Top Menu

  • Clinical Trials
  • Investors & Media
  • Careers
  • Contact Us
Menu
Close

Main navigation

  • Our Focus
  • Our Research
  • Our Medicine
  • Our Story
Home > Investors & Media > Press Releases
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Leadership
      • Board of Directors
    • Financial Information
      • SEC Filings
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
      • Dividend History
      • Analyst Coverage
    • Contact Us

Shareholder Tools

  • Email Alerts
  • Download Library
  • RSS
  • Print
  • Share
  • Facebook
  • LinkedIn
  • Twitter

Press Releases

Press Releases

Sep 21, 2021
Intercept to Present at the 2021 Cantor Virtual Global Healthcare Conference
NEW YORK , Sept. 21, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals , Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief
Read More
Sep 13, 2021
Intercept Pharmaceuticals Announces Convertible Notes Repurchase
NEW YORK , Sept. 13, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals , Inc. (Nasdaq: ICPT) (“Intercept”), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, announced today that it has entered into
Read More
Sep 01, 2021
Intercept to Present at the Virtual Baird 2021 Global Healthcare Conference
NEW YORK , Sept. 01, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals , Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief
Read More
Aug 10, 2021
Intercept Pharmaceuticals Announces Convertible Notes Exchange, New Issuance and Stock Repurchase
NEW YORK , Aug. 10, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals , Inc. (Nasdaq: ICPT) (“Intercept”), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, announced today that it has entered into
Read More
Jul 29, 2021
Intercept Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
Worldwide Ocaliva ® net sales of $96.6 million , representing 25% growth over the prior year quarter Company reiterates 2021 financial guidance of Ocaliva net sales guidance of $325 million to $340 million and Non-GAAP adjusted operating expense guidance of $380 to $410 million Updates to the
Read More
Jul 19, 2021
Intercept to Announce Second Quarter 2021 Financial Results on July 29, 2021
NEW YORK , July 19, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its second quarter 2021 financial results prior
Read More
Jun 21, 2021
Intercept to Present New NASH and PBC Data at the Digital International Liver Congress™ 2021
New analyses from the Phase 3 REGENERATE study highlight the relationship between early reductions of aminotransferases and fibrosis improvement in patients with fibrosis due to NASH treated with obeticholic acid (OCA) In a real-world study of patients with PBC, Ocaliva ® reduced alkaline
Read More
Jun 15, 2021
Intercept to Present at the Raymond James 2021 Human Health Innovation Conference
NEW YORK , June 15, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso , President and Chief
Read More
Jun 09, 2021
Intercept Appoints M. Michelle Berrey, M.D., M.P.H., as President of Research & Development and Chief Medical Officer
NEW YORK , June 09, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of M.
Read More
Jun 07, 2021
Intercept Appoints Andrew Saik as Chief Financial Officer
NEW YORK , June 07, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Andrew Saik as Chief
Read More

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Current page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page next ›
  • Last page last »
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Leadership
      • Board of Directors
    • Financial Information
      • SEC Filings
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
      • Dividend History
      • Analyst Coverage
    • Contact Us

Shareholder Tools

  • Email Alerts
  • Download Library
  • RSS
  • Print
  • Share
  • Facebook
  • LinkedIn
  • Twitter

Live - Footer Menu

  • Privacy Policy
  • Privacy Shield Policy
  • Corporate Compliance
  • Terms of Use
  • Contact Us
  • Cookie Preferences
305 Madison Avenue|Morristown, NJ 07960|T: 844-782-ICPT
© 2023 Intercept Pharmaceuticals, Inc.